{"schema_version":"1.0","type":"article","title":"GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.md","lang":"en","date":"2026-07-08","publish_at":"2026-07-08T09:10:35+08:00","updated_at":"2026-07-08","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","GLP-1","dorzagliatin","glucokinase activator","GKA","drug development","metabolic disease","type 2 diabetes","MASH","clinical data","BD licensing","biotech valuation","API / CDMO","capital markets"],"summary":"GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.","key_points":[],"facts":[],"sections":["01｜GLP-1 Has Proved Efficacy, but the Real-World Problem Is Long-Term Persistence","02｜Dorzagliatin Is Not Just Another Glucose-Lowering Drug","03｜The Real Dorzagliatin Plus GLP-1 Imagination: Less Side-Effect Pressure, More Sustainability","04｜Metabolic Drugs Are Moving From Single-Point Treatment to Combination Matrices","05｜What Taiwan Investors Should Watch: Do Not Chase GLP-1 Blindly","06｜Conclusion: The Next Weight-Loss Drug Question Is Whether the Effect Can Stay"],"references":[{"title":"Nature Medicine, [Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial](), 2022.","source":"","date":"","url":"https://www.nature.com/articles/s41591-022-01802-6"},{"title":"Nature Medicine, [Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial](), 2022.","source":"","date":"","url":"https://www.nature.com/articles/s41591-022-01803-5"},{"title":"BMJ, [Weight regain after cessation of medication for weight management: systematic review and meta-analysis](), 2026.","source":"","date":"","url":"https://www.bmj.com/content/392/bmj-2025-085304"},{"title":"FDA, [FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease](), March 14, 2024.","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease"},{"title":"New England Journal of Medicine, [Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis](), 2024.","source":"","date":"","url":"https://www.nejm.org/doi/10.1056/NEJMoa2401943"},{"title":"Disclaimer: This article is for industry research and market observation only. It does not constitute investment advice, trading advice, medical advice, fundraising advice, or a recommendation on any individual security. Biotech and pharmaceutical investing involves clinical, regulatory, licensing, commercialization, currency, and capital-market risks. Readers should make independent judgments and bear their own risk.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | GLP-1's second half is about durability, tolerability, dose pressure, and rebound risk","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-01.png"},{"alt":"Figure 2 | Dorzagliatin is framed as a glucose-sensor reset through glucokinase biology","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-02.png"},{"alt":"Figure 3 | Dorzagliatin plus GLP-1 is a combination-design question, not a simple add-on slogan","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-03.png"},{"alt":"Figure 4 | Metabolic drug development is shifting toward mechanism combinations across MASH, T2D, lipids, and uric acid","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-08）。GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last。https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}